
The USA’s Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine have said they will expand the focus of the successful Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI), a partnership established in 2013 to expedite early-stage drug discovery of innovative new therapies.
Under this expansion, Tri-I TDI will extend its current relationship with its industry partner, Japanese pharma major Takeda Pharmaceutical (TYO: 4502), from the realm of small-molecule discovery into the new research area of antibody drug discovery. All three institutions will benefit from Tri-I TDI’s expansion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze